Drug Profile
Research programme: cancer vaccines and immunotherapies - C-Pharma
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cyplasin Biomedical
- Developer C-Pharma
- Class Antibodies; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral)
- 29 Mar 2011 Cyplasin Biomedical is now called Compass Biotechnologies
- 14 Apr 2010 Preclinical trials in Cancer in Canada (Parenteral)